Responsive image
博碩士論文 etd-0810114-102730 詳細資訊
Title page for etd-0810114-102730
論文名稱
Title
軟珊瑚化合物的神經保護作用
The neuroprotectective effects of soft coral-derived compounds
系所名稱
Department
畢業學年期
Year, semester
語文別
Language
學位類別
Degree
頁數
Number of pages
133
研究生
Author
指導教授
Advisor
召集委員
Convenor
口試委員
Advisory Committee
口試日期
Date of Exam
2014-07-25
繳交日期
Date of Submission
2014-09-10
關鍵字
Keywords
帕金森氏症、活性氧物、人類神經母瘤細胞、第一型血色素氧化酵素、6-羥基多巴胺
6-OHDA, SH-SY5Y, ROS, Parkinson’s disease, HO-1
統計
Statistics
本論文已被瀏覽 5690 次,被下載 0
The thesis/dissertation has been browsed 5690 times, has been downloaded 0 times.
中文摘要
帕金森氏症(Parkinson’sdisease, PD)為患病人口僅次於阿茲海默症(Alzheimer’sdisease, AD)且常見與年齡相關的神經退化性疾病,影響全球大約0.2%的人口數。至目前為止,只有少部分的藥物可以用於抑制PD的病理進程,雖然這些藥物能有效緩解PD症狀,但也有研究指出這些藥物的使用除了會伴隨許多副作用還會造成腦內氧化壓力的傷害。在本研究中,從海洋生物中被分離出來的PWY21及PWY29,能明顯減少6-OHDA誘發人類神經母瘤細胞(human neuroblastoma, SH-SY5Y)產生的細胞毒殺及細胞凋亡的情形。而後的實驗結果則發現PWY21及PWY29是透過調節氧化壓力的方式在保護SH-SY5Y免於受到6-OHDA的傷害進而達到神經保護的功效。另外本研究亦發現PWY21及PWY29在斑馬魚PD模式中能有效改善6-OHDA造成斑馬魚運動行為能力下降。因此,本研究總結PWY21及PWY29可能具有被發展為PD候選藥物的潛力。
Abstract
Parkinson’s disease (PD), after Alzheimer’s disease, is one of most common age-related neurodegenerative diseases, affects almost 0.2% of the world population. Till date, few pharmacological agents have been isolated that effectively inhibit the progression of PD; although these agents have been proven to be effective in providing symptomatic relief against PD, they have also been reported to cause undesirable side effects that result in long-term oxidative damage. In the present study, PWY21 and PWY29 were isolated from marine organisms. They significantly reduced 6-OHDA-induced cytotoxicity and apoptosis in human neuroblastoma (SH-SY5Y). The cellular neuroprotective effect of PWY21 and PWY29 were tested in 6-OHDA-treated SH-SY5Y cells, wherein neuroprotection is mediated through modulation of oxidative stress. Moreover, we also found PWY21 and PWY29 also attenuated 6-OHDA-induced motor behavior dysfunction in zebrafish. Therefore, we conclude that PWY21 and PWY29 may be promising candidates for the treatment of PD
目次 Table of Contents
中文摘要 iii
Abstract: iv
目錄 v
圖目錄 vi
表目錄 viii
縮寫表 ix
第壹章、前言 1
第貳章、實驗材料與方法 20
第参章、實驗結果 30
第肆章、討論 88
參考文獻 102
參考文獻 References
Abraham, N. G., and Drummond, G., 2006, CD163-Mediated hemoglobin-heme uptake activates macrophage HO-1, providing an antiinflammatory function: Circulation research, v. 99, no. 9, p. 911-914.
Akimenko, M. A., Johnson, S. L., Westerfield, M., and Ekker, M., 1995, Differential induction of four msx homeobox genes during fin development and regeneration in zebrafish: Development, v. 121, no. 2, p. 347-357.
Alvarez-Fischer, D., Henze, C., Strenzke, C., Westrich, J., Ferger, B., Hoglinger, G. U., Oertel, W. H., and Hartmann, A., 2008, Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice: Exp Neurol, v. 210, no. 1, p. 182-193.
Andrew, R., Watson, D., Best, S., Midgley, J., Wenlong, H., and Petty, R., 1993, The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls: Neurochemical research, v. 18, no. 11, p. 1175-1177.
Andrews, Z. B., Horvath, B., Barnstable, C. J., Elseworth, J., Yang, L., Beal, M. F., Roth, R. H., Matthews, R. T., and Horvath, T. L., 2005, Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease: The Journal of neuroscience, v. 25, no. 1, p. 184-191.
Anichtchik, O., Diekmann, H., Fleming, A., Roach, A., Goldsmith, P., and Rubinsztein, D. C., 2008a, Loss of PINK1 function affects development and results in neurodegeneration in zebrafish: J Neurosci, v. 28, no. 33, p. 8199-8207.
-, 2008b, Loss of PINK1 function affects development and results in neurodegeneration in zebrafish: The Journal of neuroscience : the official journal of the Society for Neuroscience, v. 28, no. 33, p. 8199-8207.
Anichtchik, O. V., Huotari, M., Peitsaro, N., Haycock, J. W., Mannisto, P. T., and Panula, P., 2000a, Modulation of histamine H3 receptors in the brain of 6-hydroxydopamine-lesioned rats: The European journal of neuroscience, v. 12, no. 11, p. 3823-3832.
Anichtchik, O. V., Kaslin, J., Peitsaro, N., Scheinin, M., and Panula, P., 2004, Neurochemical and behavioural changes in zebrafish Danio rerio after systemic administration of 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Journal of neurochemistry, v. 88, no. 2, p. 443-453.
Anichtchik, O. V., Rinne, J. O., Kalimo, H., and Panula, P., 2000b, An altered histaminergic innervation of the substantia nigra in Parkinson's disease: Experimental neurology, v. 163, no. 1, p. 20-30.
Auluck, P. K., Chan, H. Y., Trojanowski, J. Q., Lee, V. M., and Bonini, N. M., 2002, Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease: Science, v. 295, no. 5556, p. 865-868.
Bai, Q., Mullett, S. J., Garver, J. A., Hinkle, D. A., and Burton, E. A., 2006, Zebrafish DJ-1 is evolutionarily conserved and expressed in dopaminergic neurons: Brain Res, v. 1113, no. 1, p. 33-44.
Barnham, K. J., Masters, C. L., and Bush, A. I., 2004, Neurodegenerative diseases and oxidative stress: Nature reviews. Drug discovery, v. 3, no. 3, p. 205-214.
Barone, M. C., Sykiotis, G. P., and Bohmann, D., 2011, Genetic activation of Nrf2 signaling is sufficient to ameliorate neurodegenerative phenotypes in a Drosophila model of Parkinson's disease: Disease models & mechanisms, v. 4, no. 5, p. 701-707.
Bechmann, I., Diano, S., Warden, C. H., Bartfai, T., Nitsch, R., and Horvath, T. L., 2002, Brain mitochondrial uncoupling protein 2 (UCP2): a protective stress signal in neuronal injury: Biochemical pharmacology, v. 64, no. 3, p. 363-367.
Ben-Shachar, D., and Youdim, M. B., 1991, Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats: Journal of neurochemistry, v. 57, no. 6, p. 2133-2135.
Bencan, Z., Sledge, D., and Levin, E. D., 2009, Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety: Pharmacology Biochemistry and Behavior, v. 94, no. 1, p. 75-80.
Biedler, J. L., Helson, L., and Spengler, B. A., 1973, Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture: Cancer Res, v. 33, no. 11, p. 2643-2652.
Block, M. L., and Hong, J. S., 2005, Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism: Progress in neurobiology, v. 76, no. 2, p. 77-98.
Bloom, F. E., Algeri, S., Groppetti, A., Revuelta, A., and Costa, E., 1969, Lesions of central norepinephrine terminals with 6-OH-dopamine: biochemistry and fine structure: Science, v. 166, no. 3910, p. 1284-1286.
Blum, D., Torch, S., Lambeng, N., Nissou, M., Benabid, A. L., Sadoul, R., and Verna, J. M., 2001, Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease: Prog Neurobiol, v. 65, no. 2, p. 135-172.
Blunt, J. W., Copp, B. R., Hu, W. P., Munro, M. H., Northcote, P. T., and Prinsep, M. R., 2009, Marine natural products: Nat Prod Rep, v. 26, no. 2, p. 170-244.
Boka, G., Anglade, P., Wallach, D., Javoy-Agid, F., Agid, Y., and Hirsch, E., 1994, Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease: Neuroscience letters, v. 172, no. 1, p. 151-154.
Bostantjopoulou, S., Kyriazis, G., Katsarou, Z., Kiosseoglou, G., Kazis, A., and Mentenopoulos, G., 1997, Superoxide dismutase activity in early and advanced Parkinson's disease: Functional neurology, v. 12, no. 2, p. 63-68.
Bozym, R. A., Patel, K., White, C., Cheung, K. H., Bergelson, J. M., Morosky, S. A., and Coyne, C. B., 2011, Calcium signals and calpain-dependent necrosis are essential for release of coxsackievirus B from polarized intestinal epithelial cells: Molecular biology of the cell, v. 22, no. 17, p. 3010-3021.
Bradshaw, J., Brittain, R., Clitherow, J., Daly, M., Jack, D., Price, B., and Stables, R., 1979, Ranitidine (AH 19065): a new potent, selective histamine H2-receptor antagonist [proceedings]: British journal of pharmacology, v. 66, no. 3, p. 464P.
Bretaud, S., Allen, C., Ingham, P. W., and Bandmann, O., 2007, p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease: Journal of neurochemistry, v. 100, no. 6, p. 1626-1635.
Bretaud, S., Lee, S., and Guo, S., 2004, Sensitivity of zebrafish to environmental toxins implicated in Parkinson's disease: Neurotoxicology and teratology, v. 26, no. 6, p. 857-864.
Brochard, V., Combadiere, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J. M., Duyckaerts, C., Flavell, R. A., Hirsch, E. C., and Hunot, S., 2009, Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease: The Journal of clinical investigation, v. 119, no. 1, p. 182-192.
Burns, J., Yokota, T., Ashihara, H., Lean, M. E., and Crozier, A., 2002, Plant foods and herbal sources of resveratrol: Journal of Agricultural and Food Chemistry, v. 50, no. 11, p. 3337-3340.
Cai, X., Jia, H., Liu, Z., Hou, B., Luo, C., Feng, Z., Li, W., and Liu, J., 2008, Polyhydroxylated fullerene derivative C(60)(OH)(24) prevents mitochondrial dysfunction and oxidative damage in an MPP(+) -induced cellular model of Parkinson's disease: Journal of neuroscience research, v. 86, no. 16, p. 3622-3634.
Carlsson, A., Engel, J., Strömbom, U., Svensson, T. H., and Waldeck, B., 1974, Suppression by dopamine-agonists of the ethanol-induced stimulation of locomotor activity and brain dopamine synthesis: Naunyn-Schmiedeberg's archives of pharmacology, v. 283, no. 2, p. 117-128.
Chakraborty, C., Hsu, C. H., Wen, Z. H., Lin, C. S., and Agoramoorthy, G., 2009, Zebrafish: a complete animal model for in vivo drug discovery and development: Curr Drug Metab, v. 10, no. 2, p. 116-124.
Chang, F., Lee, J., Navolanic, P., Steelman, L., Shelton, J., Blalock, W., Franklin, R., and McCubrey, J., 2003, Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy: Leukemia, v. 17, no. 3, p. 590-603.
Chao, J., Lau, W. K.-W., Huie, M. J., Ho, Y.-S., Yu, M.-S., Lai, C. S.-W., Wang, M., Yuen, W.-H., Lam, W. H., and Chan, T. H., 2010, A pro-drug of the green tea polyphenol (−)-epigallocatechin-3-gallate (EGCG) prevents differentiated SH-SY5Y cells from toxicity induced by 6-hydroxydopamine: Neuroscience letters, v. 469, no. 3, p. 360-364.
Chao, J., Yu, M.-S., Ho, Y.-S., Wang, M., and Chang, R. C.-C., 2008, Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity: Free Radical Biology and Medicine, v. 45, no. 7, p. 1019-1026.
Chen, A. Y., Xia, S., Wilburn, P., and Tully, T., 2014, Olfactory deficits in an alpha-synuclein fly model of Parkinson's disease: PLoS One, v. 9, no. 5, p. e97758.
Chico, T. J., Ingham, P. W., and Crossman, D. C., 2008, Modeling cardiovascular disease in the zebrafish: Trends Cardiovasc Med, v. 18, no. 4, p. 150-155.
Choi, A. M., and Alam, J., 1996, Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury: American journal of respiratory cell and molecular biology, v. 15, no. 1, p. 9-19.
Choi, H. K., Won, L. A., Kontur, P. J., Hammond, D. N., Fox, A. P., Wainer, B. H., Hoffmann, P. C., and Heller, A., 1991, Immortalization of embryonic mesencephalic dopaminergic neurons by somatic cell fusion: Brain research, v. 552, no. 1, p. 67-76.
Coelho, M. H., Silva, I. J., Azevedo, M. S., and Manso, C. F., 1991, Decrease in blood histamine in drug-treated parkinsonian patients: Molecular and chemical neuropathology / sponsored by the International Society for Neurochemistry and the World Federation of Neurology and research groups on neurochemistry and cerebrospinal fluid, v. 14, no. 2, p. 77-85.
Colton, C. A., and Gilbert, D. L., 1987, Production of superoxide anions by a CNS macrophage, the microglia: FEBS letters, v. 223, no. 2, p. 284-288.
Colucci-D'Amato, L., Perrone-Capano, C., and di Porzio, U., 2003, Chronic activation of ERK and neurodegenerative diseases: BioEssays : news and reviews in molecular, cellular and developmental biology, v. 25, no. 11, p. 1085-1095.
Cummings, J. L., 1992, Depression and Parkinson's disease: a review: The American journal of psychiatry.
Curtius, H. C., Wolfensberger, M., Steinmann, B., Redweik, U., and Siegfried, J., 1974, Mass fragmentography of dopamine and 6-hydroxydopamine: Application to the determination of dopamine in human brain biopsies from the caudate nucleus: Journal of Chromatography A, v. 99, p. 529-540.
D'Incalci, M., and Galmarini, C. M., 2010, A review of trabectedin (ET-743): a unique mechanism of action: Mol Cancer Ther, v. 9, no. 8, p. 2157-2163.
Darland, T., and Dowling, J. E., 2001, Behavioral screening for cocaine sensitivity in mutagenized zebrafish: Proc Natl Acad Sci U S A, v. 98, no. 20, p. 11691-11696.
Dauer, W., and Przedborski, S., 2003, Parkinson's disease: mechanisms and models: Neuron, v. 39, no. 6, p. 889-909.
Dennery, P. A., Wong, H. E., Sridhar, K. J., Rodgers, P. A., Sim, J. E., and Spitz, D. R., 1996, Differences in basal and hyperoxia-associated HO expression in oxidant-resistant hamster fibroblasts: The American journal of physiology, v. 271, no. 4 Pt 1, p. L672-679.
Desagher, S., and Martinou, J. C., 2000, Mitochondria as the central control point of apoptosis: Trends Cell Biol, v. 10, no. 9, p. 369-377.
Dexter, D., Wells, F., Lee, A., Agid, F., Agid, Y., Jenner, P., and Marsden, C., 1989, Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease: Journal of neurochemistry, v. 52, no. 6, p. 1830-1836.
Dexter, D. T., and Jenner, P., 2013, Parkinson disease: from pathology to molecular disease mechanisms: Free Radic Biol Med, v. 62, p. 132-144.
Dooley, K., and Zon, L. I., 2000, Zebrafish: a model system for the study of human disease: Curr Opin Genet Dev, v. 10, no. 3, p. 252-256.
Driscoll, M., and Gerstbrein, B., 2003, Dying for a cause: invertebrate genetics takes on human neurodegeneration: Nat Rev Genet, v. 4, no. 3, p. 181-194.
Eisenhofer, G., Kopin, I. J., and Goldstein, D. S., 2004, Catecholamine metabolism: a contemporary view with implications for physiology and medicine: Pharmacological reviews, v. 56, no. 3, p. 331-349.
Elyasi, L., Eftekhar-Vaghefi, S. H., and Esmaeili-Mahani, S., 2014, Morphine Protects SH-SY5Y Human Neuroblastoma Cells Against 6-Hydroxydopamine-Induced Cell Damage: Involvement of Anti-Oxidant, Calcium Blocking, and Anti-Apoptotic Properties: Rejuvenation Res, v. 17, no. 3, p. 255-263.
Emerit, J., Edeas, M., and Bricaire, F., 2004, Neurodegenerative diseases and oxidative stress: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, v. 58, no. 1, p. 39-46.
Erba, E., Bergamaschi, D., Bassano, L., Damia, G., Ronzoni, S., Faircloth, G. T., and D'Incalci, M., 2001, Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action: European journal of cancer, v. 37, no. 1, p. 97-105.
Esmaeili-Mahani, S., Vazifekhah, S., Pasban-Aliabadi, H., Abbasnejad, M., and Sheibani, V., 2013, Protective effect of orexin-A on 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells: Neurochem Int, v. 63, no. 8, p. 719-725.
Fearnley, J. M., and Lees, A. J., 1991, Ageing and Parkinson's disease: substantia nigra regional selectivity: Brain, v. 114 ( Pt 5), p. 2283-2301.
Feitsma, H., and Cuppen, E., 2008, Zebrafish as a cancer model: Mol Cancer Res, v. 6, no. 5, p. 685-694.
Feng, C. W., Wen, Z. H., Huang, S. Y., Hung, H. C., Chen, C. H., Yang, S. N., Chen, N. F., Wang, H. M., Hsiao, C. D., and Chen, W. F., 2014, Effects of 6-hydroxydopamine exposure on motor activity and biochemical expression in zebrafish (danio rerio) larvae: Zebrafish, v. 11, no. 3, p. 227-239.
Flinn, L., Mortiboys, H., Volkmann, K., Koster, R. W., Ingham, P. W., and Bandmann, O., 2009a, Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio): Brain, v. 132, no. Pt 6, p. 1613-1623.
-, 2009b, Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio): Brain : a journal of neurology, v. 132, no. Pt 6, p. 1613-1623.
Fouquet, B., Weinstein, B. M., Serluca, F. C., and Fishman, M. C., 1997, Vessel patterning in the embryo of the zebrafish: guidance by notochord: Developmental biology, v. 183, no. 1, p. 37-48.
Foy, C. J., Passmore, A. P., Vahidassr, M. D., Young, I. S., and Lawson, J. T., 1999, Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease: QJM : monthly journal of the Association of Physicians, v. 92, no. 1, p. 39-45.
Frémont, L., 2000, Biological effects of resveratrol: Life sciences, v. 66, no. 8, p. 663-673.
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W. Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., Eidelberg, D., and Fahn, S., 2001, Transplantation of embryonic dopamine neurons for severe Parkinson's disease: The New England journal of medicine, v. 344, no. 10, p. 710-719.
Friling, R. S., Bensimon, A., Tichauer, Y., and Daniel, V., 1990, Xenobiotic-inducible expression of murine glutathione S-transferase Ya subunit gene is controlled by an electrophile-responsive element: Proceedings of the National Academy of Sciences, v. 87, no. 16, p. 6258-6262.
Fry, M. J., 1994, Structure, regulation and function of phosphoinositide 3-kinases: Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, v. 1226, no. 3, p. 237-268.
Garcia-Rocha, M., Garcia-Gravalos, M. D., and Avila, J., 1996, Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15: Br J Cancer, v. 73, no. 8, p. 875-883.
Gatto, N. M., Rhodes, S. L., Manthripragada, A. D., Bronstein, J., Cockburn, M., Farrer, M., and Ritz, B., 2010, alpha-Synuclein gene may interact with environmental factors in increasing risk of Parkinson's disease: Neuroepidemiology, v. 35, no. 3, p. 191-195.
Geng, X., Tian, X., Tu, P., and Pu, X., 2007, Neuroprotective effects of echinacoside in the mouse MPTP model of Parkinson's disease: European journal of pharmacology, v. 564, no. 1-3, p. 66-74.
Gerlach, M., Gsell, W., Kornhuber, J., Jellinger, K., Krieger, V., Pantucek, F., Vock, R., and Riederer, P., 1996, A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome: Brain Res, v. 741, no. 1-2, p. 142-152.
Gerlai, R., Chatterjee, D., Pereira, T., Sawashima, T., and Krishnannair, R., 2009, Acute and chronic alcohol dose: population differences in behavior and neurochemistry of zebrafish: Genes, Brain and Behavior, v. 8, no. 6, p. 586-599.
German, D. C., Manaye, K., Smith, W. K., Woodward, D. J., and Saper, C. B., 1989, Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization: Annals of neurology, v. 26, no. 4, p. 507-514.
Glezer, I., Lapointe, A., and Rivest, S., 2006, Innate immunity triggers oligodendrocyte progenitor reactivity and confines damages to brain injuries: FASEB journal : official publication of the Federation of American Societies for Experimental Biology, v. 20, no. 6, p. 750-752.
Gomez-Lazaro, M., Galindo, M. F., Concannon, C. G., Segura, M. F., Fernandez-Gomez, F. J., Llecha, N., Comella, J. X., Prehn, J. H., and Jordan, J., 2008, 6-Hydroxydopamine activates the mitochondrial apoptosis pathway through p38 MAPK-mediated, p53-independent activation of Bax and PUMA: Journal of neurochemistry, v. 104, no. 6, p. 1599-1612.
Granato, A., Gores, G., Vilei, M. T., Tolando, R., Ferraresso, C., and Muraca, M., 2003, Bilirubin inhibits bile acid induced apoptosis in rat hepatocytes: Gut, v. 52, no. 12, p. 1774-1778.
Greco, D., Volpicelli, F., Di Lieto, A., Leo, D., Perrone-Capano, C., Auvinen, P., and di Porzio, U., 2009, Comparison of gene expression profile in embryonic mesencephalon and neuronal primary cultures: PLoS One, v. 4, no. 3, p. e4977.
Greene, L. A., and Tischler, A. S., 1976, Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor: Proc Natl Acad Sci U S A, v. 73, no. 7, p. 2424-2428.
Guo, S., Bezard, E., and Zhao, B., 2005, Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway: Free Radic Biol Med, v. 39, no. 5, p. 682-695.
Guo, S., Yan, J., Yang, T., Yang, X., Bezard, E., and Zhao, B., 2007, Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson’s disease through inhibition of ROS-NO pathway: Biological psychiatry, v. 62, no. 12, p. 1353-1362.
Haavik, J., and Toska, K., 1998, Tyrosine hydroxylase and Parkinson's disease: Molecular neurobiology, v. 16, no. 3, p. 285-309.
Halliwell, B., and Aruoma, O. I., 1991, DNA damage by oxygen-derived species. Its mechanism and measurement in mammalian systems: FEBS Lett, v. 281, no. 1-2, p. 9-19.
Hara, H., Ohta, M., and Adachi, T., 2006, Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway: Journal of neuroscience research, v. 84, no. 4, p. 860-866.
Hefti, F., Melamed, E., Sahakian, B. J., and Wurtman, R. J., 1980, Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA: Pharmacol Biochem Behav, v. 12, no. 2, p. 185-188.
Herbomel, P., Thisse, B., and Thisse, C., 1999, Ontogeny and behaviour of early macrophages in the zebrafish embryo: Development, v. 126, no. 17, p. 3735-3745.
Hirsch, E., Brandel, J. P., Galle, P., Javoy‐Agid, F., and Agid, Y., 1991, Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis: Journal of neurochemistry, v. 56, no. 2, p. 446-451.
Hirsch, E. C., and Hunot, S., 2009, Neuroinflammation in Parkinson's disease: a target for neuroprotection?: Lancet neurology, v. 8, no. 4, p. 382-397.
Hirsch, E. C., Hunot, S., Damier, P., and Faucheux, B., 1998, Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?: Annals of neurology, v. 44, no. 3 Suppl 1, p. S115-120.
Hoehn, M. M., and Yahr, M. D., 1967, Parkinsonism: onset, progression and mortality: Neurology, v. 17, no. 5, p. 427-442.
Hornykiewicz, O., 1966, Dopamine (3-hydroxytyramine) and brain function: Pharmacol Rev, v. 18, no. 2, p. 925-964.
Huang, S. T., Ho, C. S., Lin, C. M., Fang, H. W., and Peng, Y. X., 2008, Development and biological evaluation of C(60) fulleropyrrolidine-thalidomide dyad as a new anti-inflammation agent: Bioorganic & medicinal chemistry, v. 16, no. 18, p. 8619-8626.
Hunot, S., Boissiere, F., Faucheux, B., Brugg, B., Mouatt-Prigent, A., Agid, Y., and Hirsch, E., 1996, Nitric oxide synthase and neuronal vulnerability in Parkinson's disease: Neuroscience, v. 72, no. 2, p. 355-363.
Huo, C., Wan, S., Lam, W., Li, L., Wang, Z., Landis-Piwowar, K., Chen, D., Dou, Q., and Chan, T., 2008, The challenge of developing green tea polyphenols as therapeutic agents: Inflammopharmacology, v. 16, no. 5, p. 248-252.
Hwang, Y. P., and Jeong, H. G., 2008, The coffee diterpene kahweol induces heme oxygenase-1 via the PI3K and p38/Nrf2 pathway to protect human dopaminergic neurons from 6-hydroxydopamine-derived oxidative stress: FEBS Lett, v. 582, no. 17, p. 2655-2662.
Ihara, Y., Chuda, M., Kuroda, S., and Hayabara, T., 1999, Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data: Journal of the neurological sciences, v. 170, no. 2, p. 90-95.
Ikeda, Y., Tsuji, S., Satoh, A., Ishikura, M., Shirasawa, T., and Shimizu, T., 2008, Protective effects of astaxanthin on 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells: J Neurochem, v. 107, no. 6, p. 1730-1740.
Jagatha, B., Mythri, R. B., Vali, S., and Bharath, M. M., 2008, Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies: Free radical biology & medicine, v. 44, no. 5, p. 907-917.
Jakel, R. J., Kern, J. T., Johnson, D. A., and Johnson, J. A., 2005, Induction of the protective antioxidant response element pathway by 6-hydroxydopamine in vivo and in vitro: Toxicological Sciences, v. 87, no. 1, p. 176-186.
Jenner, P., 2003, Oxidative stress in Parkinson's disease: Ann Neurol, v. 53 Suppl 3, p. S26-36; discussion S36-28.
Jin, F., Wu, Q., Lu, Y.-F., Gong, Q.-H., and Shi, J.-S., 2008, Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats: European journal of pharmacology, v. 600, no. 1, p. 78-82.
Jin, Y., Chen, R., Liu, W., and Fu, Z., 2010, Effect of endocrine disrupting chemicals on the transcription of genes related to the innate immune system in the early developmental stage of zebrafish (Danio rerio): Fish Shellfish Immunol, v. 28, no. 5-6, p. 854-861.
Junn, E., and Mouradian, M. M., 2001, Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases: J Neurochem, v. 78, no. 2, p. 374-383.
Kanagaraj, N., Beiping, H., Dheen, S. T., and Tay, S. S., 2014, Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins: Neuroscience, v. 272, p. 167-179.
Kazimi, N., and Cahill, G. M., 1999, Development of a circadian melatonin rhythm in embryonic zebrafish: Brain research. Developmental brain research, v. 117, no. 1, p. 47-52.
Kem, W. R., 2000, The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21): Behav Brain Res, v. 113, no. 1-2, p. 169-181.
Kim, S.-U., Park, Y.-H., Min, J.-S., Sun, H.-N., Han, Y.-H., Hua, J.-M., Lee, T.-H., Lee, S.-R., Chang, K.-T., and Kang, S. W., 2013, Peroxiredoxin I is a ROS/p38 MAPK-dependent inducible antioxidant that regulates NF-κB-mediated iNOS induction and microglial activation: Journal of neuroimmunology, v. 259, no. 1, p. 26-36.
Kim, S., Park, S. E., Sapkota, K., Kim, M. K., and Kim, S. J., 2011, Leaf extract of Rhus verniciflua Stokes protects dopaminergic neuronal cells in a rotenone model of Parkinson's disease: The Journal of pharmacy and pharmacology, v. 63, no. 10, p. 1358-1367.
Kong, A.-N. T., Owuor, E., Yu, R., Hebbar, V., Chen, C., Hu, R., and Mandlekar, S., 2001, Induction of xenobiotic enzymes by the map kinase pathway and the antioxidant or electrophile response element (ARE/EpRE) 1* 2, 3: Drug metabolism reviews, v. 33, no. 3-4, p. 255-271.
Kwon, S. H., Kim, J. A., Hong, S. I., Jung, Y. H., Kim, H. C., Lee, S. Y., and Jang, C. G., 2011, Loganin protects against hydrogen peroxide-induced apoptosis by inhibiting phosphorylation of JNK, p38, and ERK 1/2 MAPKs in SH-SY5Y cells: Neurochemistry international, v. 58, no. 4, p. 533-541.
Laddha, S. S., and Bhatnagar, S. P., 2009, A new therapeutic approach in Parkinson's disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents: Bioorganic & medicinal chemistry, v. 17, no. 19, p. 6796-6802.
Lamberti, P., Zoccolella, S., Iliceto, G., Armenise, E., Fraddosio, A., De Mari, M., and Livrea, P., 2005, Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients: Movement disorders, v. 20, no. 1, p. 69-72.
Langheinrich, U., Vacun, G., and Wagner, T., 2003, Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia: Toxicology and applied pharmacology, v. 193, no. 3, p. 370-382.
Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., and Karluk, D., 1999, Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure: Annals of neurology, v. 46, no. 4, p. 598-605.
Lee, H. J., Noh, Y. H., Lee, D. Y., Kim, Y. S., Kim, K. Y., Chung, Y. H., Lee, W. B., and Kim, S. S., 2005, Baicalein attenuates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells: Eur J Cell Biol, v. 84, no. 11, p. 897-905.
Levesque, S., Wilson, B., Gregoria, V., Thorpe, L. B., Dallas, S., Polikov, V. S., Hong, J. S., and Block, M. L., 2010, Reactive microgliosis: extracellular micro-calpain and microglia-mediated dopaminergic neurotoxicity: Brain : a journal of neurology, v. 133, no. Pt 3, p. 808-821.
Leveugle, B., Faucheux, B., Bouras, C., Nillesse, N., Spik, G., Hirsch, E., Agid, Y., and Hof, P., 1996, Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson’s disease cases: Acta neuropathologica, v. 91, no. 6, p. 566-572.
Levites, Y., Youdim, M. B., Maor, G., and Mandel, S., 2002, Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures: Biochem Pharmacol, v. 63, no. 1, p. 21-29.
Li, J., and Yuan, J., 2008, Caspases in apoptosis and beyond: Oncogene, v. 27, no. 48, p. 6194-6206.
Li, Y., and Jaiswal, A., 1992, Regulation of human NAD (P) H: quinone oxidoreductase gene. Role of AP1 binding site contained within human antioxidant response element: Journal of Biological Chemistry, v. 267, no. 21, p. 15097-15104.
Liang, Z., Shi, F., Wang, Y., Lu, L., Zhang, Z., Wang, X., and Wang, X., 2011, Neuroprotective effects of tenuigenin in a SH-SY5Y cell model with 6-OHDA-induced injury: Neurosci Lett, v. 497, no. 2, p. 104-109.
Liedhegner, E. A., Steller, K. M., and Mieyal, J. J., 2011, Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson's disease: Chemical research in toxicology, v. 24, no. 10, p. 1644-1652.
Lieschke, G. J., and Currie, P. D., 2007, Animal models of human disease: zebrafish swim into view: Nat Rev Genet, v. 8, no. 5, p. 353-367.
Lin, T.-K., Chen, S.-D., Chuang, Y.-C., Lin, H.-Y., Huang, C.-R., Chuang, J.-H., Wang, P.-W., Huang, S.-T., Tiao, M.-M., and Chen, J.-B., 2014, Resveratrol Partially Prevents Rotenone-Induced Neurotoxicity in Dopaminergic SH-SY5Y Cells through Induction of Heme Oxygenase-1 Dependent Autophagy: International journal of molecular sciences, v. 15, no. 1, p. 1625-1646.
Lindner, M. D., Plone, M. A., Francis, J. M., and Emerich, D. F., 1996, Validation of a rodent model of Parkinson's disease: evidence of a therapeutic window for oral Sinemet: Brain research bulletin, v. 39, no. 6, p. 367-372.
Linker, R. A., Lee, D. H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., Ellrichmann, G., Bruck, W., Dawson, K., Goelz, S., Wiese, S., Scannevin, R. H., Lukashev, M., and Gold, R., 2011, Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway: Brain : a journal of neurology, v. 134, no. Pt 3, p. 678-692.
Liu, B., Gao, H. M., Wang, J. Y., Jeohn, G. H., Cooper, C. L., and Hong, J. S., 2002, Role of nitric oxide in inflammation-mediated neurodegeneration: Annals of the New York Academy of Sciences, v. 962, p. 318-331.
Long-Smith, C. M., Sullivan, A. M., and Nolan, Y. M., 2009, The influence of microglia on the pathogenesis of Parkinson's disease: Progress in neurobiology, v. 89, no. 3, p. 277-287.
Lopes da Fonseca, T., Correia, A., Hasselaar, W., van der Linde, H. C., Willemsen, R., and Outeiro, T. F., 2013, The zebrafish homologue of Parkinson's disease ATP13A2 is essential for embryonic survival: Brain Res Bull, v. 90, p. 118-126.
Maehama, T., and Dixon, J. E., 1998, The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate: Journal of Biological Chemistry, v. 273, no. 22, p. 13375-13378.
Makhija, D. T., and Jagtap, A. G., 2014, Studies on sensitivity of zebrafish as a model organism for Parkinson's disease: Comparison with rat model: J Pharmacol Pharmacother, v. 5, no. 1, p. 39-46.
Maki, K. C., McKenney, J. M., Reeves, M. S., Lubin, B. C., and Dicklin, M. R., 2008, Effects of Adding Prescription Omega-3 Acid Ethyl Esters to< i> Simvastatin</i>(20 mg/day) on Lipids and Lipoprotein Particles in Men and Women With Mixed Dyslipidemia: The American journal of cardiology, v. 102, no. 4, p. 429-433.
Maraganore, D. M., Harding, A. E., and Marsden, C. D., 1991, A clinical and genetic study of familial Parkinson's disease: Movement disorders : official journal of the Movement Disorder Society, v. 6, no. 3, p. 205-211.
Martinez, A., 2007, Marine-derived drugs in neurology: Curr Opin Investig Drugs, v. 8, no. 7, p. 525-530.
Matés, J., 2000, Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology: Toxicology, v. 153, no. 1-3, p. 83-104.
Mateo, I., Infante, J., Sánchez‐Juan, P., García‐Gorostiaga, I., Rodríguez‐Rodríguez, E., Vázquez‐Higuera, J., Berciano, J., and Combarros, O., 2010, Serum heme oxygenase‐1 levels are increased in Parkinson’s disease but not in Alzheimer’s disease: Acta Neurologica Scandinavica, v. 121, no. 2, p. 136-138.
Mathur, P., and Guo, S., 2011, Differences of acute versus chronic ethanol exposure on anxiety-like behavioral responses in zebrafish: Behavioural brain research, v. 219, no. 2, p. 234-239.
Mattiasson, G., Shamloo, M., Gido, G., Mathi, K., Tomasevic, G., Yi, S., Warden, C. H., Castilho, R. F., Melcher, T., and Gonzalez-Zulueta, M., 2003, Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma: Nature medicine, v. 9, no. 8, p. 1062-1068.
McGeer, E. G., Klegeris, A., and McGeer, P. L., 2005, Inflammation, the complement system and the diseases of aging: Neurobiology of aging, v. 26 Suppl 1, p. 94-97.
McGeer, P. L., and McGeer, E. G., 2004, Inflammation and neurodegeneration in Parkinson's disease: Parkinsonism & related disorders, v. 10 Suppl 1, p. S3-7.
McGeer, P. L., Schwab, C., Parent, A., and Doudet, D., 2003, Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: Annals of neurology, v. 54, no. 5, p. 599-604.
McIlwain, D. R., Berger, T., and Mak, T. W., 2013, Caspase functions in cell death and disease: Cold Spring Harb Perspect Biol, v. 5, no. 4, p. a008656.
McKinley, E. T., Baranowski, T. C., Blavo, D. O., Cato, C., Doan, T. N., and Rubinstein, A. L., 2005, Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons: Brain research. Molecular brain research, v. 141, no. 2, p. 128-137.
Melamed, E., 1979, Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease: Archives of neurology, v. 36, no. 5, p. 308-310.
Merchant, R. A., Li, B., Yap, K.-B., and Ng, T.-P., 2009, Use of drugs with anticholinegic effects and cognitive impairment in community-living older persons: Age and ageing, v. 38, no. 1, p. 105-108.
Moi, P., Chan, K., Asunis, I., Cao, A., and Kan, Y. W., 1994, Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region: Proceedings of the National Academy of Sciences, v. 91, no. 21, p. 9926-9930.
Morale, M. C., Serra, P. A., L'Episcopo, F., Tirolo, C., Caniglia, S., Testa, N., Gennuso, F., Giaquinta, G., Rocchitta, G., Desole, M. S., Miele, E., and Marchetti, B., 2006, Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration: Neuroscience, v. 138, no. 3, p. 869-878.
Moussaoui, S., Obinu, M. C., Daniel, N., Reibaud, M., Blanchard, V., and Imperato, A., 2000, The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease: Experimental neurology, v. 166, no. 2, p. 235-245.
Nakaso, K., Ito, S., and Nakashima, K., 2008, Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells: Neuroscience letters, v. 432, no. 2, p. 146-150.
Nakaso, K., Nakamura, C., Sato, H., Imamura, K., Takeshima, T., and Nakashima, K., 2006, Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins: Biochemical and biophysical research communications, v. 339, no. 3, p. 915-922.
Napoli, I., and Neumann, H., 2009, Microglial clearance function in health and disease: Neuroscience, v. 158, no. 3, p. 1030-1038.
Neuzil, J., and Stocker, R., 1994, Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation: The Journal of biological chemistry, v. 269, no. 24, p. 16712-16719.
Nguyen, T., Huang, H., and Pickett, C. B., 2000, Transcriptional regulation of the antioxidant response element Activation by Nrf2 and repression by MafK: Journal of Biological Chemistry, v. 275, no. 20, p. 15466-15473.
Nilsson, G., 1996, Brain and body oxygen requirements of Gnathonemus petersii, a fish with an exceptionally large brain: The Journal of experimental biology, v. 199, no. Pt 3, p. 603-607.
Norton, W., and Bally-Cuif, L., 2010, Adult zebrafish as a model organism for behavioural genetics: BMC Neurosci, v. 11, p. 90.
Okada, S., Nakamura, M., Katoh, H., Miyao, T., Shimazaki, T., Ishii, K., Yamane, J., Yoshimura, A., Iwamoto, Y., Toyama, Y., and Okano, H., 2006, Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury: Nature medicine, v. 12, no. 7, p. 829-834.
Ono, K., and Han, J., 2000, The p38 signal transduction pathway: activation and function: Cellular signalling, v. 12, no. 1, p. 1-13.
Orr, C. F., Rowe, D. B., and Halliday, G. M., 2002, An inflammatory review of Parkinson's disease: Progress in neurobiology, v. 68, no. 5, p. 325-340.
Ossola, B., Schendzielorz, N., Chen, S. H., Bird, G. S., Tuominen, R. K., Mannisto, P. T., and Hong, J. S., 2011, Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected]: Neuropharmacology, v. 61, no. 4, p. 574-582.
Ouyang, M., and Shen, X., 2006, Critical role of ASK1 in the 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells: J Neurochem, v. 97, no. 1, p. 234-244.
Panula, P., Yang, H. Y., and Costa, E., 1984, Comparative distribution of bombesin/GRP- and substance-P-like immunoreactivities in rat hypothalamus: The Journal of comparative neurology, v. 224, no. 4, p. 606-617.
Paré, W. P., and Temple, L. J., 1973, Food deprivation, shock stress and stomach lesions in the rat: Physiology & behavior, v. 11, no. 3, p. 371-375.
Park, H. J., Kim, H. J., Park, H. K., and Chung, J. H., 2009, Protective effect of histamine H2 receptor antagonist ranitidine against rotenone-induced apoptosis: Neurotoxicology, v. 30, no. 6, p. 1114-1119.
Parkinson, J., 1817, An Essay on the Shaking: neuropsychiatry and clinical neurosciences, v. 14, p. 223-236.
Parng, C., Roy, N. M., Ton, C., Lin, Y., and McGrath, P., 2007, Neurotoxicity assessment using zebrafish: J Pharmacol Toxicol Methods, v. 55, no. 1, p. 103-112.
Peretz, C., Chillag-Talmor, O., Linn, S., Gurevich, T., El-Ad, B., Silverman, B., Friedman, N., and Giladi, N., 2014, Parkinson's disease patients first treated at age 75 years or older: a comparative study: Parkinsonism & related disorders, v. 20, no. 1, p. 69-74.
Perry, V. H., 2012, Innate inflammation in Parkinson's disease: Cold Spring Harb Perspect Med, v. 2, no. 9, p. a009373.
Polazzi, E., and Contestabile, A., 2002, Reciprocal interactions between microglia and neurons: from survival to neuropathology: Reviews in the neurosciences, v. 13, no. 3, p. 221-242.
Porter, A. G., and Jänicke, R. U., 1999, Emerging roles of caspase-3 in apoptosis: Cell death and differentiation, v. 6, no. 2, p. 99-104.
Porter, C. C., Totaro, J. A., and Stone, C. A., 1963, Effect of 6-hydroxydopamine and some other compounds on the concentration of norepinephrine in the hearts of mice: J Pharmacol Exp Ther, v. 140, p. 308-316.
Primiano, T., Kensler, T. W., Kuppusamy, P., Zweier, J. L., and Sutter, T. R., 1996, Induction of hepatic heme oxygenase-1 and ferritin in rats by cancer chemopreventive dithiolethiones: Carcinogenesis, v. 17, no. 11, p. 2291-2296.
Proksch, P., Edrada, R. A., and Ebel, R., 2002, Drugs from the seas - current status and microbiological implications: Appl Microbiol Biotechnol, v. 59, no. 2-3, p. 125-134.
Przedborski, S., 2007, Neuroinflammation and Parkinson's disease: Handbook of clinical neurology, v. 83, p. 535-551.
Qian, Y., Fritzsch, B., Shirasawa, S., Chen, C. L., Choi, Y., and Ma, Q., 2001, Formation of brainstem (nor)adrenergic centers and first-order relay visceral sensory neurons is dependent on homeodomain protein Rnx/Tlx3: Genes Dev, v. 15, no. 19, p. 2533-2545.
Quesada, A., Lee, B. Y., and Micevych, P. E., 2008, PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease: Developmental neurobiology, v. 68, no. 5, p. 632-644.
Ren, G., Xin, S., Li, S., Zhong, H., and Lin, S., 2011, Disruption of LRRK2 does not cause specific loss of dopaminergic neurons in zebrafish: PloS one, v. 6, no. 6, p. e20630.
Reynolds, A. D., Banerjee, R., Liu, J., Gendelman, H. E., and Mosley, R. L., 2007, Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease: Journal of leukocyte biology, v. 82, no. 5, p. 1083-1094.
Ridley, S. H., Sarsfield, S. J., Lee, J. C., Bigg, H. F., Cawston, T. E., Taylor, D. J., DeWitt, D. L., and Saklatvala, J., 1997, Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels: Journal of immunology, v. 158, no. 7, p. 3165-3173.
Riederer, P., Sofic, E., Rausch, W. D., Schmidt, B., Reynolds, G. P., Jellinger, K., and Youdim, M. B., 1989, Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains: Journal of neurochemistry, v. 52, no. 2, p. 515-520.
Rihel, J., Prober, D. A., Arvanites, A., Lam, K., Zimmerman, S., Jang, S., Haggarty, S. J., Kokel, D., Rubin, L. L., Peterson, R. T., and Schier, A. F., 2010, Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation: Science, v. 327, no. 5963, p. 348-351.
Rink, E., and Wullimann, M. F., 2001, The teleostean (zebrafish) dopaminergic system ascending to the subpallium (striatum) is located in the basal diencephalon (posterior tuberculum): Brain research, v. 889, no. 1-2, p. 316-330.
Rinne, J. O., Ruottinen, H. M., Nagren, K., Aberg, L. E., and Santavuori, P., 2002, Positron emission tomography shows reduced striatal dopamine D1 but not D2 receptors in juvenile neuronal ceroid lipofuscinosis: Neuropediatrics, v. 33, no. 3, p. 138-141.
Ros-Bernal, F., Hunot, S., Herrero, M. T., Parnadeau, S., Corvol, J. C., Lu, L., Alvarez-Fischer, D., Carrillo-de Sauvage, M. A., Saurini, F., Coussieu, C., Kinugawa, K., Prigent, A., Hoglinger, G., Hamon, M., Tronche, F., Hirsch, E. C., and Vyas, S., 2011, Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism: Proceedings of the National Academy of Sciences of the United States of America, v. 108, no. 16, p. 6632-6637.
Roux, P. P., and Blenis, J., 2004, ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions: Microbiology and molecular biology reviews, v. 68, no. 2, p. 320-344.
Rubinstein, A. L., 2003, Zebrafish: from disease modeling to drug discovery: Current opinion in drug discovery & development, v. 6, no. 2, p. 218-223.
Rushmore, T. H., and Pickett, C., 1990, Transcriptional regulation of the rat glutathione S-transferase Ya subunit gene. Characterization of a xenobiotic-responsive element controlling inducible expression by phenolic antioxidants: Journal of Biological Chemistry, v. 265, no. 24, p. 14648-14653.
Sapkota, K., Kim, S., Kim, M. K., and Kim, S. J., 2010, A detoxified extract of Rhus verniciflua Stokes upregulated the expression of BDNF and GDNF in the rat brain and the human dopaminergic cell line SH-SY5Y: Bioscience, biotechnology, and biochemistry, v. 74, no. 10, p. 1997-2004.
Sapkota, K., Kim, S., Park, S. E., and Kim, S. J., 2011, Detoxified extract of Rhus verniciflua stokes inhibits rotenone-induced apoptosis in human dopaminergic cells, SH-SY5Y: Cellular and molecular neurobiology, v. 31, no. 2, p. 213-223.
Satoh, T., Okamoto, S. I., Cui, J., Watanabe, Y., Furuta, K., Suzuki, M., Tohyama, K., and Lipton, S. A., 2006, Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers: Proc Natl Acad Sci U S A, v. 103, no. 3, p. 768-773.
Schüle, B., Pera, R. A. R., and Langston, J. W., 2009, Can cellular models revolutionize drug discovery in Parkinson's disease?: Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, v. 1792, no. 11, p. 1043-1051.
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., and Garbe, E., 2007, Dopamine agonists and the risk of cardiac-valve regurgitation: New England Journal of Medicine, v. 356, no. 1, p. 29-38.
Schipper, H. M., 2004, Heme oxygenase expression in human central nervous system disorders: Free Radical Biology and Medicine, v. 37, no. 12, p. 1995-2011.
Schipper, H. M., Song, W., Zukor, H., Hascalovici, J. R., and Zeligman, D., 2009, Heme oxygenase‐1 and neurodegeneration: expanding frontiers of engagement: Journal of neurochemistry, v. 110, no. 2, p. 469-485.
Schwab, M. L., and Lewis, A. E., 1969, An improved stain for Heinz bodies: Technical bulletin of the Registry of Medical Technologists, v. 39, no. 4, p. 93-95.
Schwab, R. S., England, A. C., Jr., Poskanzer, D. C., and Young, R. R., 1969, Amantadine in the treatment of Parkinson's disease: JAMA : the journal of the American Medical Association, v. 208, no. 7, p. 1168-1170.
Senoh, S., Creveling, C. R., Udenfriend, S., and Witkop, B., 1959a, Chemical, Enzymatic and Metabolic Studies on the Mechanism of Oxidation of Dopamine1: Journal of the American Chemical Society, v. 81, no. 23, p. 6236-6240.
Senoh, S., Witkop, B., Creveling, C., and Udenfriend, S., 1959b, 2, 4, 5-Trihydroxyphenethylamine, a new metabolite of 3, 4-dihydroxyphenethylamine: Journal of the American Chemical Society, v. 81, no. 7, p. 1768-1769.
Senoh, S., Witkop, B., Creveling, C.R., Udenfriend, S., 1959, 2,4,5-tri-hydroxyphenetylamine, a new matbolite of 3,4-dihydroxyphenetylamine.: J. Am. Chem. Soc., v. 81, p. 1768–1769.
Sharma, G. M., and Burkholder, P. R., 1967, Studies on the antimicrobial substances of sponges. II. Structure and synthesis of a bromine-containing antibacterial compound from a marine sponge: Tetrahedron letters, v. 42, p. 4147-4150.
Shaul, Y. D., and Seger, R., 2007, The MEK/ERK cascade: from signaling specificity to diverse functions: Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, v. 1773, no. 8, p. 1213-1226.
Sheng, D., Qu, D., Kwok, K. H., Ng, S. S., Lim, A. Y., Aw, S. S., Lee, C. W., Sung, W. K., Tan, E. K., Lufkin, T., Jesuthasan, S., Sinnakaruppan, M., and Liu, J., 2010a, Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect: PLoS genetics, v. 6, no. 4, p. e1000914.
-, 2010b, Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect: PLoS Genet, v. 6, no. 4, p. e1000914.
Shulman, J. M., De Jager, P. L., and Feany, M. B., 2011, Parkinson's disease: genetics and pathogenesis: Annu Rev Pathol, v. 6, p. 193-222.
Simonian, N. A., and Coyle, J. T., 1996, Oxidative stress in neurodegenerative diseases: Annual review of pharmacology and toxicology, v. 36, p. 83-106.
Son, O. L., Kim, H. T., Ji, M. H., Yoo, K. W., Rhee, M., and Kim, C. H., 2003, Cloning and expression analysis of a Parkinson's disease gene, uch-L1, and its promoter in zebrafish: Biochem Biophys Res Commun, v. 312, no. 3, p. 601-607.
Stocker, R., Yamamoto, Y., McDonagh, A. F., Glazer, A. N., and Ames, B. N., 1987, Bilirubin is an antioxidant of possible physiological importance: Science, v. 235, no. 4792, p. 1043-1046.
Taamma, A., Misset, J. L., Riofrio, M., Guzman, C., Brain, E., Lopez Lazaro, L., Rosing, H., Jimeno, J. M., and Cvitkovic, E., 2001, Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v. 19, no. 5, p. 1256-1265.
Taguchi, K., Motohashi, H., and Yamamoto, M., 2011, Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution: Genes Cells, v. 16, no. 2, p. 123-140.
Teismann, P., Vila, M., Choi, D. K., Tieu, K., Wu, D. C., Jackson-Lewis, V., and Przedborski, S., 2003, COX-2 and neurodegeneration in Parkinson's disease: Annals of the New York Academy of Sciences, v. 991, p. 272-277.
Tenhunen, R., Marver, H. S., and Schmid, R., 1968, The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase: Proc Natl Acad Sci U S A, v. 61, no. 2, p. 748-755.
Tetrud, J. W., and Langston, J. W., 1989, The effect of deprenyl (selegiline) on the natural history of Parkinson's disease: Science, v. 245, no. 4917, p. 519-522.
Tian, L.-L., Zhou, Z., Zhang, Q., Sun, Y.-N., Li, C.-R., Cheng, C., Zhong, Z.-Y., and Wang, S.-Q., 2007, Protective effect of (±) isoborneol against 6-OHDA-induced apoptosis in SH-SY5Y cells: Cellular Physiology and Biochemistry, v. 20, no. 6, p. 1019-1032.
Turkseven, S., Kruger, A., Mingone, C. J., Kaminski, P., Inaba, M., Rodella, L. F., Ikehara, S., Wolin, M. S., and Abraham, N. G., 2005, Antioxidant mechanism of heme oxygenase-1 involves an increase in superoxide dismutase and catalase in experimental diabetes: American journal of physiology. Heart and circulatory physiology, v. 289, no. 2, p. H701-707.
Ueda, K., Ueyama, T., Oka, M., Ito, T., Tsuruo, Y., and Ichinose, M., 2009, Polaprezinc (Zinc L-carnosine) is a potent inducer of anti-oxidative stress enzyme, heme oxygenase (HO)-1 - a new mechanism of gastric mucosal protection: Journal of pharmacological sciences, v. 110, no. 3, p. 285-294.
Ugarte, S. D., Lin, E., Klann, E., Zigmond, M. J., and Perez, R. G., 2003, Effects of GDNF on 6‐OHDA‐induced death in a dopaminergic cell line: Modulation by inhibitors of PI3 kinase and MEK: Journal of neuroscience research, v. 73, no. 1, p. 105-112.
Ungerstedt, U., 1968, 6-Hydroxy-dopamine induced degeneration of central monoamine neurons: Eur J Pharmacol, v. 5, no. 1, p. 107-110.
Uttara, B., Singh, A. V., Zamboni, P., and Mahajan, R. T., 2009, Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options: Curr Neuropharmacol, v. 7, no. 1, p. 65-74.
Wirdefeldt, K., Adami, H. O., Cole, P., Trichopoulos, D., and Mandel, J., 2011, Epidemiology and etiology of Parkinson's disease: a review of the evidence: European journal of epidemiology, v. 26 Suppl 1, p. S1-58.
Wruck, C. J., Claussen, M., Fuhrmann, G., Romer, L., Schulz, A., Pufe, T., Waetzig, V., Peipp, M., Herdegen, T., and Gotz, M. E., 2007, Luteolin protects rat PC12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway: Journal of neural transmission. Supplementum, no. 72, p. 57-67.
WU, R. M., Mohanakumar, K. P., Murphy, D. L., and Chiueh, C. C., 1994, Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline): Annals of the New York Academy of Sciences, v. 738, no. 1, p. 214-221.
Xiao, H., Lv, F., Xu, W., Zhang, L., Jing, P., and Cao, X., 2011, Deprenyl prevents MPP(+)-induced oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 expression through the activation of PI3K/Akt and Erk: Toxicology, v. 290, no. 2-3, p. 286-294.
Xie, H. R., Hu, L. S., and Li, G. Y., 2010, SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease: Chin Med J (Engl), v. 123, no. 8, p. 1086-1092.
Yamaguchi, T., Terakado, M., Horio, F., Aoki, K., Tanaka, M., and Nakajima, H., 1996, Role of bilirubin as an antioxidant in an ischemia-reperfusion of rat liver and induction of heme oxygenase: Biochemical and biophysical research communications, v. 223, no. 1, p. 129-135.
Yang, Y.-C., Lii, C.-K., Lin, A.-H., Yeh, Y.-W., Yao, H.-T., Li, C.-C., Liu, K.-L., and Chen, H.-W., 2011, Induction of glutathione synthesis and heme oxygenase 1 by the flavonoids butein and phloretin is mediated through the ERK/Nrf2 pathway and protects against oxidative stress: Free Radical Biology and Medicine, v. 51, no. 11, p. 2073-2081.
Ye, Q., Huang, B., Zhang, X., Zhu, Y., and Chen, X., 2012, Astaxanthin protects against MPP+-induced oxidative stress in PC12 cells via the HO-1/NOX2 axis: BMC neuroscience, v. 13, no. 1, p. 156.
Youdim, M., and Tipton, K., 2002, Rat striatal monoamine oxidase-B inhibition by< i> l</i>-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease: Parkinsonism & related disorders, v. 8, no. 4, p. 247-253.
Zarubin, T., and Han, J., 2005, Activation and signaling of the p38 MAP kinase pathway: Cell research, v. 15, no. 1, p. 11-18.
Zecca, L., Zucca, F. A., Wilms, H., and Sulzer, D., 2003, Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics: Trends in neurosciences, v. 26, no. 11, p. 578-580.
Zhang, Z., Cui, W., Li, G., Yuan, S., Xu, D., Hoi, M. P., Lin, Z., Dou, J., Han, Y., and Lee, S. M., 2012a, Baicalein protects against 6-OHDA-induced neurotoxicity through activation of Keap1/Nrf2/HO-1 and involving PKCα and PI3K/AKT signaling pathways: Journal of agricultural and food chemistry, v. 60, no. 33, p. 8171-8182.
Zhang, Z. J., Cheang, L. C., Wang, M. W., and Lee, S. M., 2011, Quercetin exerts a neuroprotective effect through inhibition of the iNOS/NO system and pro-inflammation gene expression in PC12 cells and in zebrafish: International journal of molecular medicine, v. 27, no. 2, p. 195-203.
Zhang, Z. J., Cheang, L. C., Wang, M. W., Li, G. H., Chu, I. K., Lin, Z. X., and Lee, S. M., 2012b, Ethanolic extract of fructus Alpinia oxyphylla protects against 6-hydroxydopamine-induced damage of PC12 cells in vitro and dopaminergic neurons in zebrafish: Cellular and molecular neurobiology, v. 32, no. 1, p. 27-40.
Zhao, D. L., Zou, L. B., Lin, S., Shi, J. G., and Zhu, H. B., 2007, Anti-apoptotic effect of esculin on dopamine-induced cytotoxicity in the human neuroblastoma SH-SY5Y cell line: Neuropharmacology, v. 53, no. 6, p. 724-732.
Zheng, L., Lin, X., Wu, N., Liu, M., Zheng, Y., Sheng, J., Ji, X., and Sun, M., 2013, Targeting cellular apoptotic pathway with peptides from marine organisms: Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, v. 1836, no. 1, p. 42-48.
Zhou, C., Huang, Y., and Przedborski, S., 2008, Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance: Ann N Y Acad Sci, v. 1147, p. 93-104.
Zong, W. X., and Thompson, C. B., 2006, Necrotic death as a cell fate: Genes & development, v. 20, no. 1, p. 1-15.
電子全文 Fulltext
本電子全文僅授權使用者為學術研究之目的,進行個人非營利性質之檢索、閱讀、列印。請遵守中華民國著作權法之相關規定,切勿任意重製、散佈、改作、轉貼、播送,以免觸法。
論文使用權限 Thesis access permission:自定論文開放時間 user define
開放時間 Available:
校內 Campus:永不公開 not available
校外 Off-campus:永不公開 not available

您的 IP(校外) 位址是 18.204.35.30
論文開放下載的時間是 校外不公開

Your IP address is 18.204.35.30
This thesis will be available to you on Indicate off-campus access is not available.

紙本論文 Printed copies
紙本論文的公開資訊在102學年度以後相對較為完整。如果需要查詢101學年度以前的紙本論文公開資訊,請聯繫圖資處紙本論文服務櫃台。如有不便之處敬請見諒。
開放時間 available 永不公開 not available

QR Code